Research & Development

Erasca, Eli Lilly partner for colorectal cancer therapy trial

Erasca and Eli Lilly and Company have signed a clinical trial partnership and supply agreement to evaluate ERAS-007, an oral ERK1/2 inhibitor, in combination with Eli Lilly's anti-EGFR antibody cetuximab (ERBITUX).

Salubris secures funding to advance complex biologics for various diseases

Salubris Biotherapeutics has secured $32m in financing from Shenzhen Salubris Pharmaceuticals to advance its new complex biologics for oncology, cardiovascular and neurodegenerative diseases.

Helsinn, BridgeBio update infigratinib collaboration for oncology indications

Helsinn Group has announced an update to its existing collaboration with BridgeBio Pharma to develop, produce and commercialise infigratinib for oncology indications in the US.

Epsilogen to develop antibodies for cancer treatment with new funding

Epsilogen has raised $41.011m (£30.75m) in a Series B funding round led by new investor Novartis Venture Fund to further develop IgE-based antibody candidates for cancer treatment.

Rondo raises funding to advance solid tumour immuno-oncology platform

Biopharmaceutical firm Rondo Therapeutics has raised $67m in a Series A financing round to advance next-generation immuno-oncology platform to treat solid tumours.

ENA Respiratory partners with COPD Foundation for antiviral nasal spray

ENA Respiratory has collaborated with not-for-profit organisation COPD Foundation for the development of INNA-051, a pan-antiviral nasal spray, for chronic lung diseases patients.

Synthego raises $200m to accelerate discoveries of new therapeutics

Genome engineering firm Synthego has raised $200m in Series E funding round to accelerate the development of CRISPR-based medicines from early-phase clinical research.

Nurosene, Cyclica partner for neurodegenerative disease drug development

Nurosene Health, through its subsidiary NetraMark, has collaborated with Cyclica for the development of new drugs to treat neurodegenerative diseases.

Seismic raises $101m to advance two drug programmes to clinic

Seismic Therapeutic has raised $101m in Series A financing led by Lightspeed Venture Partners to advance its first two lead drug programmes to the clinic.